BYON-4413

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameBYON-4413
Drug Alias NameBYON-4413
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD123
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlandsSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesByondis Bv
China Registration ClassN/A

Develop Information

Active CompaniesByondis Bv
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A